March 2004
Worldwide Biotech;Mar2004, Vol. 16 Issue 3, p1
Trade Publication
Deals with the partnership between Enzon Pharmaceuticals, Inc. and Inex Pharmaceuticals Corp. for the development and commercialization of the drug Onco TCS of Inex.


Related Articles

  • Enzon and Inex seek Canadian approval for lymphoma drug.  // PharmaWatch: Cancer;December2004, Vol. 3 Issue 12, p13 

    Reports that Enzon Pharmaceuticals Inc. and Inex Pharmaceuticals Corp. have filed a new drug submission (NDS) with the Therapeutics Products Directorate of Health Canada for its proprietary anticancer drug, Marqibo, in non-Hodgkin's lymphoma (NHL). Intention of NDS to seek marketing approval in...

  • Lymphoma News Headlines May 15, 2004--June 14, 2004.  // PharmaWatch: Cancer;July 2004, Vol. 3 Issue 7, p13 

    Presents news headlines on lymphoma for the period May 15 through June 14, 2004. Data supporting the effectivity of Rituxan in the treatment of non-Hodgkin's lymphoma; Studies on the use of Bexxar on non-Hodgkin's lymphoma from Corixa and GlaxoSmithKline; U.S. Food and Drug Administration's...

  • Inex and Enzon reveal FDA acceptance of Onco TCS new drug application.  // PharmaWatch: Cancer;July 2004, Vol. 3 Issue 7, p14 

    Reports on the revelation made by Inex Pharmaceuticals Corp. and Enzon Pharmaceuticals that the new drug application for Onco TCS vincrisine sulfate liposomes injection was accepted by the U.S. Food and Drug Administration and was granted a standard review designation. Target date for the...

  • Enzon terminates Inex agreements.  // PharmaWatch: Biotechnology;May 2005, Vol. 4 Issue 5, p15 

    Reports that Enzon Pharmaceuticals (EP) has terminated its partnership with Inex Pharmaceuticals Corp. (IPC) for the development and commercialization of Inex's proprietary oncology product, Marqibo. Agreement of EP on contractual obligations, including development expenses and milestone...

  • Who Is Moving On and Up?  // Pharmaceutical Executive;Feb2004, Vol. 24 Issue 2, p114 

    Reports developments on the pharmaceutical industry as of February 2004 in the U.S. Strategic partnership formed by Enzon Pharmaceuticals Inc. and Inex Pharmaceuticals Corp. to develop and commercialize the Onco TCS oncology product of Inex; Creation of a new management and business development...

  • Inex and Enzon complete new drug application filing for Onco TCS.  // PharmaWatch: Cancer;May 2004, Vol. 3 Issue 5, p13 

    Reports that Inex Pharmaceuticals and Enzon Pharmaceuticals have completed the filing of a new drug application (NDA) to the U.S. Food and Drug Administration for Onco TCS, a single-agent treatment for patients with relapsed aggressive non-Hodgkin's lymphoma previously treated with at least two...

  • Enzon reports net loss for fiscal year.  // Biotech Financial Reports;Oct99, p7 

    Reports on Piscataway, New Jersey Enzon Inc.'s announcement of a net loss for the year ended June 30, 1999. Comparison of the 1999 net loss with 1998; Research and development expenses for the year; Increase in selling, general and administrative expenses for the year.

  • Abe's out.  // Business News New Jersey;5/1/96, Vol. 9 Issue 9, p2 

    Reports on Abe Abuchowski's resignation as chairman of biotechnology firm Enzon. Aqbuchowski's relinquishment of all his responsibilities as an employee of the company; Staff changes in the company; Problems with Abuchowski's handling of matters involving clinical trials for Enzon's artificial...

  • Enzon wins over the drug giants. Goldblatt, Dan // Business News New Jersey;06/02/97, Vol. 10 Issue 18, p18 

    Presents information on Enzon, a biotechnology company in Piscataway, New Jersey. Companies relationship with big businesses; Comments from John A. Caruso, vice president for business development; Information on licensing deals; How small drug firms can attract the attention of big...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics